Ampio Competitors
AMPE Stock | USD 0.82 0.01 1.23% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Ampio Pharm competition on your existing holdings.
Ampio |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ampio Pharm's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ampio Pharm Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ampio Pharm and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ampio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ampio Pharm does not affect the price movement of the other competitor.
A | MBIO | MBRX | CLVRW | MCRB | MDGL | EQ | KA | ME | ||
A | -0.72 | -0.17 | -0.08 | -0.67 | 0.68 | 0.62 | -0.76 | -0.62 | A | |
MBIO | -0.72 | 0.37 | 0.03 | 0.75 | -0.55 | -0.57 | 0.64 | 0.61 | MBIO | |
MBRX | -0.17 | 0.37 | -0.59 | 0.66 | -0.06 | -0.38 | 0.43 | 0.52 | MBRX | |
CLVRW | -0.08 | 0.03 | -0.59 | -0.45 | 0.09 | 0.44 | -0.42 | -0.54 | CLVRW | |
MCRB | -0.67 | 0.75 | 0.66 | -0.45 | -0.46 | -0.74 | 0.82 | 0.84 | MCRB | |
MDGL | 0.68 | -0.55 | -0.06 | 0.09 | -0.46 | 0.53 | -0.63 | -0.57 | MDGL | |
EQ | 0.62 | -0.57 | -0.38 | 0.44 | -0.74 | 0.53 | -0.77 | -0.76 | EQ | |
KA | -0.76 | 0.64 | 0.43 | -0.42 | 0.82 | -0.63 | -0.77 | 0.93 | KA | |
ME | -0.62 | 0.61 | 0.52 | -0.54 | 0.84 | -0.57 | -0.76 | 0.93 | ME | |
A | MBIO | MBRX | CLVRW | MCRB | MDGL | EQ | KA | ME |
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ampio Stock performing well and Ampio Pharm Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ampio Pharm's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
A | 1.10 | (0.10) | (0.02) | 0.06 | 1.43 | 2.27 | 5.92 | |||
MBIO | 3.06 | (0.52) | 0.00 | (0.26) | 0.00 | 5.30 | 20.58 | |||
MBRX | 5.08 | (0.70) | 0.00 | (3.03) | 0.00 | 11.19 | 34.21 | |||
CLVRW | 9.30 | 2.23 | 0.25 | 2.07 | 7.03 | 29.03 | 74.95 | |||
MCRB | 4.27 | (0.76) | 0.00 | (0.13) | 0.00 | 8.70 | 29.80 | |||
MDGL | 3.67 | 0.13 | 0.05 | 0.20 | 4.45 | 8.89 | 24.70 | |||
EQ | 6.22 | 1.61 | 0.27 | 0.46 | 5.96 | 20.33 | 70.42 | |||
KA | 4.98 | (2.49) | 0.00 | (1.49) | 0.00 | 8.68 | 72.56 | |||
ME | 4.89 | (1.02) | 0.00 | (0.16) | 0.00 | 10.61 | 34.64 |
Cross Equities Net Income Analysis
Compare Ampio Pharm and related stocks such as Agilent Technologies, Mustang Bio, and Moleculin Biotech Net Income Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | 257 M | 1.2 B | 724 M | 497 M | 398 M | 460 M | 684 M | 316 M | 1.1 B | 719 M | 1.2 B | 1.3 B | 1.2 B | 1.4 B | 1.5 B |
MBIO | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (12.7 M) | (31.3 M) | (30.7 M) | (48.2 M) | (62.1 M) | (64.1 M) | (78.9 M) | (51.6 M) | (54.2 M) |
MBRX | (365.8 K) | (365.8 K) | (365.8 K) | (365.8 K) | (365.8 K) | (365.8 K) | (3.9 M) | (9.8 M) | (11.9 M) | (13.2 M) | (15 M) | (8.9 M) | (27.4 M) | (29.8 M) | (28.3 M) |
CLVRW | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (48.1 M) | (41.4 M) | (45.6 M) | (66.1 M) | (41.6 M) | (43.7 M) |
MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (64.2 M) | (86.5 M) | (61.5 M) | (253.8 M) | (113.7 M) | (119.4 M) |
MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (299.3 M) | (373.6 M) | (354.9 M) |
EQ | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (13.2 M) | (25.6 M) | (29.8 M) | (39 M) | (107.7 M) | (13.3 M) | (14 M) |
KA | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (59.1 M) | (13.9 M) | (12 M) | (63.1 M) | (14.1 M) | (14.8 M) |
ME | (183.5 M) | (183.5 M) | (183.5 M) | (183.5 M) | (183.5 M) | (183.5 M) | (183.5 M) | (183.5 M) | (183.5 M) | (289.3 M) | (183.4 M) | (217.5 M) | (311.7 M) | (280.5 M) | (294.5 M) |
Ampio Pharm and related stocks such as Agilent Technologies, Mustang Bio, and Moleculin Biotech Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ampio Pharm financial statement analysis. It represents the amount of money remaining after all of Ampio Pharm operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ampio Pharm Competitive Analysis
The better you understand Ampio Pharm competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ampio Pharm's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ampio Pharm's competition over several years is one of the best ways to analyze its investment potential.Better Than Average | Worse Than Peers | View Performance Chart |
Ampio Pharm Competition Performance Charts
Five steps to successful analysis of Ampio Pharm Competition
Ampio Pharm's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ampio Pharm in relation to its competition. Ampio Pharm's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Ampio Pharm in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ampio Pharm's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ampio Pharm, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Ampio Pharm position
In addition to having Ampio Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Russia On Wall Street Thematic Idea Now
Russia On Wall Street
Cross-sector and cross-instrument bundle of publicly traded Russian entities that are expected to be listed on USA exchanges or over the counter. The Russia On Wall Street theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Russia On Wall Street Theme or any other thematic opportunities.
View All Next | Launch |
Check out Ampio Pharm Correlation with its peers. For information on how to trade Ampio Stock refer to our How to Trade Ampio Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Ampio Stock analysis
When running Ampio Pharm's price analysis, check to measure Ampio Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ampio Pharm is operating at the current time. Most of Ampio Pharm's value examination focuses on studying past and present price action to predict the probability of Ampio Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ampio Pharm's price. Additionally, you may evaluate how the addition of Ampio Pharm to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Ampio Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ampio Pharm. If investors know Ampio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ampio Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.70) | Return On Assets (0.47) | Return On Equity (0.92) |
The market value of Ampio Pharm is measured differently than its book value, which is the value of Ampio that is recorded on the company's balance sheet. Investors also form their own opinion of Ampio Pharm's value that differs from its market value or its book value, called intrinsic value, which is Ampio Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ampio Pharm's market value can be influenced by many factors that don't directly affect Ampio Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ampio Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ampio Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ampio Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.